ABSTRACT The iC-GPC Assay (iCubate, Huntsville, AL) is a qualitative multiplex test for the detection of five of the most common Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, and Enterococcus faecium) responsible for bacterial bloodstream infections, performed directly from positive blood cultures. The assay also detects the presence of the mecA, vanA, and vanB resistance determinants. This study comparatively evaluated the performance of the iC-GPC Assay against the Verigene Gram-positive blood culture (BC-GP) assay (Luminex Corp., Austin, TX) for 1,134 patient blood culture specimens positive for Gram-positive cocci. The iC-GPC Assay had an overall percent agreement with the BC-GP assay of 95.5%. Discordant specimens were further analyzed by PCR and a bidirectional sequencing method. The results indicate that the iC-GPC Assay together with the iCubate system is an accurate and reliable tool for the detection of the five most common Gram-positive bacteria and their resistance markers responsible for bloodstream infections.
B
acterial sepsis and its associated complications are a major cause of morbidity and the 10th leading cause of mortality in the United States (1) . Early diagnosis and the institution of appropriate antimicrobial therapy are vital for favorable patient outcomes. Unfortunately, traditional culture and antimicrobial susceptibility test methods are time-dependent processes that often require 2 to 4 days before final test results are available.
Within recent years, a variety of methods have been developed for the rapid identification of bacterial pathogens in positive blood culture broths. These methods include peptide nucleic acid fluorescence in situ hybridization (PNA-FISH), matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), real-time PCR (RT-PCR) assays, and microarray-based tests (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The availability of these methods to reliably identify a specific bacterial agent as the cause of bloodstream infection (BSI) within one to several hours of culture positivity has resulted in significant reductions in the time to appropriate antimicrobial therapy, length of hospital stays, mortality rates, and cost of care (7, 8, (12) (13) (14) . An additional benefit from the use of some of these assays is that they concomitantly detect the presence of important resistance gene markers for methicillin resistance (mecA), vancomycin resistance (vanA or vanB), extended-spectrum beta-lactamases, and carbapenemases (12, 13, (15) (16) (17) .
The iC-GPC Assay (iCubate, Huntsville, AL) is a molecular target amplification assay were then inoculated into BD Bactec Plus Aerobic/F blood culture bottles with 10 ml human blood added. The inoculated bottles were incubated on the Bactec 9050 system until positivity. Frozen aliquots were provided randomized and blinded to the clinical sites. PCR/bidirectional sequencing assays. PCR and bidirectional sequencing assays were used for resistance marker confirmation and for arbitration of discrepant results between the iC-GPC Assay and the Verigene BC-GP assay. PCR and bidirectional sequencing assays were developed and validated by the LabCorp Perimeter Park Genomics Facility (Morrisville, NC). Briefly, PCR primers with incorporated M13 priming sites were designed to amplify unique regions of iC-GPC Assay target organisms. Frozen aliquots of clinical specimens were used to prepare fresh subcultures. Nucleic acid extraction was performed from pure isolates using a validated NucliSENS easyMAG procedure. The extracted DNA was tested using the specified PCR assay, and amplification was confirmed by analysis on an Agarose 1000 gel. Purified PCR products were sequenced with M13 universal sequencing primers using the BigDye Terminator cycle sequencing kit to achieve bidirectional coverage. Raw data were analyzed using Sequence Analysis Software. The assays were designed to generate sequencing amplicons of Ն200 bp with trace scores of Ͼ20 and to yield consensus sequences that aligned to the target sequences when analyzed using the NCBI Basic Local Alignment Search Tool (BLAST). Table 1 shows the comparative performances of the iC-GPC and Verigene BC-GP assays as well as the resolution of the discordant results after arbitration testing. Overall, there was very good positive and negative agreement for each of the bacterial targets and antibiotic resistance determinants evaluated. For S. aureus, the overall positive and negative percent agreements were 97.0% and 99.8%, respectively, in which the iC-GPC Assay had eight false-negative and two false-positive results compared to the Verigene BC-GP assay. After arbitration testing of these discordant results, one of eight iC-GPC false-negative results was confirmed as a true negative for S. aureus, and one of two false-positive results was confirmed as a true positive for S. aureus. For S. epidermidis, both the positive and negative percent agreement between the two assays was 98.3%. The iC-GPC Assay had 4 false-negative and 14 false-positive results compared to the Verigene assay. After arbitration testing, one of four falsenegative results was confirmed as a true negative for S. epidermidis, while 9 of the 14 false positives were confirmed as true positives for S. epidermidis.
RESULTS
The results for S. pneumoniae produced a comparative positive percent agreement of 93.7% and a negative percent agreement of 99.9%. All four of the false-negative iC-GPC Assay results were confirmed as true negatives for S. pneumoniae, and the one false-positive result was confirmed as a true positive for S. pneumoniae by PCR and bidirectional sequencing resolution testing. Due to a positive percent agreement of less than 95% and because of the small prospective sample size, all discordant specimens were further characterized by traditional culture-based methods (MALDI-TOF MS). MALDI-TOF MS confirmed the iC-GPC Assay result for all five discordant samples.
For the enterococci, E. faecalis had 98.7% positive and a 99.9% negative overall agreement between the iC-GPC Assay and Verigene assay. Of the two false-negative results, one was confirmed as a true negative for E. faecalis, while the one false positive was confirmed as a true false positive for E. faecalis. For E. faecium, the positive percent agreement was 98.6%, and the negative percent agreement was 99.8%. The one false-negative result was confirmed as a true false negative for E. faecium, while one of the two false-positive results was confirmed as a true positive for E. faecium.
For the detection of the antibiotic resistance determinants, the mecA gene had 96.1% positive agreement and 95.2% negative agreement between the two assays. Of the 274 observed true-positive mecA results, 269/274 (98.2%) were confirmed as mecA positive by PCR and bidirectional sequencing. The iC-GPC Assay had 11 false-negative and 11 false-positive results compared to the Verigene assay. After arbitration testing, 1 of the 11 false-negative results was confirmed as a true negative for mecA, while 8 of the 11 false-positive results were confirmed as true positives for mecA.
For the vanA determinant, the positive and negative agreements between the two assays were 98.3% and 96.9%, respectively. Of the 19 observed true-positive vanA results, 19/19 (100%) were confirmed as vanA positive by PCR and bidirectional sequencing. The one false-negative result was confirmed as a true false negative for vanA, while two of the five false positives were confirmed as true positives for vanA. The positive and negative agreements for the vanB resistance determinant were 100% and 99.4%, respectively. Of the 2 observed true-positive vanB results, 2/2 (100%) were confirmed as vanB positive by PCR and bidirectional sequencing. The one false-positive iC-GPC Assay result was confirmed as a true positive for vanB following arbitration testing.
The iC-GPC Assay was also evaluated across three of the most common types of blood culture bottle systems, BacT/Alert, Bactec, and VersaTREK. iC-GPC Assay target performance by blood culture bottle type is presented in Table 2 . The overall percent agreements for prospective specimens collected in the various medium types are as follows: BacT/Alert medium, 95.5% (378/396); Bactec medium, 94.4% (234/248); and VersaTREK medium, 93.7% (252/269). When the performance of the iC-GPC Assay was compared against the BC-GP assay, there was no statistical difference observed between the study sites and the types of blood culture bottles used.
A total of seven specimens were identified as mixed cultures for iC-GPC Assay target organisms by one or both assays (Table 3) . One discrepant mixed sample was identified by the iC-GPC Assay to contain a target not detected by the Verigene BC-GP assay. The false-positive vanA result was confirmed by PCR/bidirectional sequencing to be negative for vanA. One discrepant mixed sample was identified by the Verigene BC-GP assay to contain targets not detected by the iC-GPC Assay. The false-negative S. aureus and mecA targets were confirmed as true positives by PCR/bidirectional sequencing.
Overall, the iC-GPC Assay compared favorably to the Verigene BC-GP assay, with an overall percent agreement of 95.5%. After arbitration testing of all discordant results between the iC-GPC Assay and Verigene BC-GP assay, the iC-GPC Assay agreed with the PCR/sequencing method for 31 specimens, while the Verigene method had agreement for 36 specimens. These results demonstrate that the iC-GPC Assay performs comparably to the Verigene BC-GP assay in this study.
DISCUSSION
Gram-positive cocci are important causes of bloodstream infections, of which S. aureus, S. epidermidis, S. pneumoniae, E. faecalis, and E. faecium represent the most common isolates. Rapid characterization of these bacteria, along with the detection of their major antibiotic resistance determinants, favorably impacts patient care and outcomes. Patient survival rates directly correlate with the early characterization of these isolates, as mortality rates can increase 7.6% for every hour that treatment is delayed (20) .
As is common with most molecular assays intended for BSI diagnosis, the iC-GPC Assay detects the most common resistance markers for methicillin and vancomycin resistance. Rapid detection of mecA, vanA, and vanB can inform treatment decisions days before traditional antimicrobial susceptibility testing (AST) results are available. However, the resistance markers detected by the iC-GPC Assay are not the only mechanisms of resistance to their respective antibiotic classes. For example, genes, (22) . In general, bacteria are constantly evolving mechanisms to combat antibiotics. As such, no PCR-based molecular diagnostic will be able to detect all genes that confer resistance to a specific class of antibiotics, let alone single nucleotide polymorphisms.
For these reasons, all molecular diagnostics recommend performing traditional culture and AST analysis in parallel in case undetected mechanisms of antibiotic resistance are present in an isolate. The results of this study have shown that the iC-GPC Assay is comparable in performance to the Verigene BC-GP assay and provides a reliable molecular alternative for the detection of five of the most common causes of Gram-positive bacterial bloodstream infections and their antibiotic resistance determinants. As with all molecular assays, there are drawbacks to the iC-GPC Assay. First, the iC-GPC Assay has limited species coverage. While the assay does not cover all the causative organisms of Gram-positive bloodstream infections, it does cover the most common and clinically relevant species. Many of the species not covered in the assay are considered common blood culture contaminants. Off-panel organisms, such as Micrococcus spp., can be pathogenic but are more commonly detected as contaminants (19, 23, 24) . The limitations of a smaller panel can also be seen in a positive light given that the cost per test will be lower than those for some of the more expansive panels currently on the market. A second limitation of the assay is the 4-h run time. The iC-GPC Assay has a longer run time than several other assays currently on the market. However, the open-access nature of the iC-Processor and the flexible time to testing minimize the impact of the longer run time.
While drawbacks exist for the iC-GPC Assay and for molecular diagnostics in general, the iCubate system offers several benefits. First, the iC-GPC Assay is performed in a single closed-system disposable cassette. This feature allows for a very simplified "load and go" assay that requires only a few minutes of a technologist's setup time. Loading the cassette is quick and easy, requiring only a single pipetting step, and it involves no additional dilutions, reagents, hydrations, or tubes. Second, the use of the closedsystem cassette greatly reduces the risk of aerosolized infectious microorganisms during specimen processing and amplicon contamination. This not only protects lab personnel, but it also essentially eliminates the chance of carryover contamination between assays. Third, the iC-Processor is capable of simultaneous random access processing of up to four cassettes on an instrument platform that has a relatively small footprint (17" by 17" by 16"). If a laboratory requires greater throughput, additional iC-Processors can be linked together while only requiring a single iC-Reader. Finally, the iC-GPC Assay provides a significantly more affordable alternative, particularly for smallto medium-sized health care institutions, for the molecular detection of common Gram-positive bacteria responsible for bloodstream infections and their resistance markers. Collectively, these benefits may positively impact technologist safety, workflow, costs, and throughput compared to other FDA-cleared molecular platforms and direct detection blood culture assays. Most importantly, the use of direct detection molecular blood culture assays, such as the iC-GPC Assay, will significantly reduce morbidity and mortality rates, shorten hospital stays, decrease costs, and favorably impact hospital antibiotic stewardship programs (25) (26) (27) (28) (29) .
